EventMutlu Erdoğan

CRISPR/Cas-mediated Directed Evolution for Protein Engineering

Proteins engineered through directed evolution are used to manufacture everything from biofuels to pharmaceuticals. Moreover, antibody-based drugs evolved using protein engineering methods can be employed in therapeutics. However, recent directed evolution methods apply isolated protein engineering schemes in tube without cell context. Yet, for engineering of many protein types, the proper context for phenotypic selection is mammalian or human cells, but generating protein libraries in mammalian cells still faces numerous challenges. Here I present a versatile approach based on CRISPR/Cas-mediated protein diversification that allows producing panels of mammalian cells expressing diversified heterologous protein libraries. Customizing the properties for precise conditions of specific sub-cellular compartments of mammalian cells can be especially useful for optimization of various proteins such as antibodies. Overall, the procedure might become valuable for engineering and tailoring the properties of large numbers of proteins for which mammalian cell context or localization in organelles is necessary.

Cas9 mediated protein engineering

About The Speaker

mutlu_photo2 copy

Dr. Mutlu Erdogan received his B.S. from Ankara University Biology Department in 2007 and obtained his Ph.D. degree from UNAM, Bilkent University in 2014. His doctoral studies were based on biophotonic applications of ultrafast fiber lasers for sub-cellular nanosurgery and biomaterial surface modification. After receiving his PhD, he started his postdoctoral studies at the Max Planck Institute of Neurobiology in Martinsried, Germany. His postdoctoral research is focused on development of a novel method for in situ protein engineering and implementation of CRISPR/Cas9 genome editing system with an intra-organelle directed evolution strategy. Dr. Erdogan is currently holding support by Co-Funded Brain Circulation Scheme 2 program for his research project on development of novel, RNA editing-based protein engineering methods expanding into antibody engineering and immunotherapy applications.